Alkermes Strategy After Antidepressant Failures Doubted By Wall Street

With a pair of Phase III failures for its major depression disorder candidate ALKS-5461, Alkermes is pinning hopes on a third pivotal trial plus ad hoc analysis of a failed study – a strategy analysts find unlikely to prevail.